Title:Nano Architect-Based Targeted Delivery Systems for Diabetic Nephropathy:
A Review
Volume: 24
Issue: 8
Author(s): Aruna Rawat, Vikas Jhawat*Rohit Dutt
Affiliation:
- Department of Pharmaceutical Science, School of Medical and Allied Science, GD Goenka University, Gurugram,
Haryana, India
Keywords:
Diabetic nephropathy, nano architect, solubility enhancement, pathophysiology, diabetes mellitus, hyperglycemia.
Abstract: Diabetes mellitus is a long-lasting disease that is very common in the age group above
20 years and is characterized by hyperglycemia with other complications like Diabetic Nephropathy
(DN). The management of DN focuses on mainly four regions: reduction of cardiovascular
risks, control of blood glycemic levels, control of the blood pressure (BP) profile, and the use of
therenin-angiotensin system (RAS). Although BP management and RAS-acting agents can postpone
the onset of DN, they cannot prevent it. In the modern era, nanotechnological interventions
have spread rapidly in the field of medicine. Patient defiance is considered important in diabetes
management when long-term or continuous management is required. Nano pharmaceuticals have
been shown to increase compliance of diabetic patients by providing multiple ways of drug delivery,
controlling release profile, increasing biological steadiness, targeting efficacy, and decreasing
toxic profile. Nanoscale formulations of botanical antidiabetic molecules improve clinical efficacy
and treatment compliance by overcoming associated biopharmaceutical and pharmacokinetic barriers.
Therefore, the development of nanopharmaceuticals can be considered to be a possible answer
to attain the finest scientific effect of the plant-based anti-diabetic molecule. Nevertheless, further
studies are needed to create clinical research-based and therapeutically effective nanoforms of antidiabetic
plant-based molecules to combat the most dreaded disease of diabetes and its known present
complications.
